The present disclosure is directed to pharmaceutical formulations comprising antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S). Other embodiments of the disclosure include the use of pharmaceutical formulations for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses, or the S protein thereof, and conditions where neutralization or inhibition of coronaviruses, or the S protein thereof, would be therapeutically and/or prophylactically beneficial.